Hill-Rom Holdings Inc (HRC) SVP Andreas G. Frank Sells 6,870 Shares of Stock

Hill-Rom Holdings Inc (NYSE:HRC) SVP Andreas G. Frank sold 6,870 shares of Hill-Rom Holdings stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $77.48, for a total transaction of $532,287.60. Following the transaction, the senior vice president now owns 16,701 shares of the company’s stock, valued at approximately $1,293,993.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hill-Rom Holdings Inc (NYSE:HRC) traded down 1.81% during trading on Friday, hitting $75.60. 1,612,576 shares of the stock were exchanged. The firm has a market cap of $4.98 billion, a PE ratio of 44.06 and a beta of 1.21. The stock’s 50-day moving average price is $75.30 and its 200-day moving average price is $75.12. Hill-Rom Holdings Inc has a 12-month low of $50.50 and a 12-month high of $84.65.

Hill-Rom Holdings (NYSE:HRC) last posted its quarterly earnings data on Friday, July 28th. The medical technology company reported $0.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The company had revenue of $689.10 million during the quarter, compared to analyst estimates of $695.50 million. During the same quarter last year, the firm posted $0.81 EPS. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, equities analysts expect that Hill-Rom Holdings Inc will post $3.82 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 15th will be given a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.95%. Hill-Rom Holdings’s dividend payout ratio (DPR) is 41.62%.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/09/16/hill-rom-holdings-inc-hrc-svp-andreas-g-frank-sells-6870-shares-of-stock.html.

Several large investors have recently bought and sold shares of the company. Lord Abbett & CO. LLC boosted its position in shares of Hill-Rom Holdings by 535.6% during the 2nd quarter. Lord Abbett & CO. LLC now owns 543,398 shares of the medical technology company’s stock valued at $43,260,000 after purchasing an additional 457,898 shares in the last quarter. Koch Industries Inc. bought a new position in shares of Hill-Rom Holdings during the 2nd quarter valued at about $1,007,000. Ameritas Investment Partners Inc. boosted its position in shares of Hill-Rom Holdings by 2.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 17,910 shares of the medical technology company’s stock valued at $1,426,000 after purchasing an additional 378 shares in the last quarter. Nomura Holdings Inc. bought a new position in shares of Hill-Rom Holdings during the 2nd quarter valued at about $332,000. Finally, 361 Capital LLC boosted its position in shares of Hill-Rom Holdings by 68.3% during the 2nd quarter. 361 Capital LLC now owns 22,886 shares of the medical technology company’s stock valued at $1,822,000 after purchasing an additional 9,287 shares in the last quarter. Institutional investors own 82.31% of the company’s stock.

A number of brokerages have issued reports on HRC. BidaskClub cut shares of Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research cut shares of Hill-Rom Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Needham & Company LLC cut their target price on shares of Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, July 28th. Barclays PLC lifted their target price on shares of Hill-Rom Holdings from $80.00 to $86.00 and gave the stock an “overweight” rating in a research report on Friday, June 9th. Finally, Morgan Stanley lifted their target price on shares of Hill-Rom Holdings from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 30th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Hill-Rom Holdings currently has a consensus rating of “Buy” and an average target price of $88.17.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Insider Buying and Selling by Quarter for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply